P600: Democratic deliberation to assess Veteran preferences for biosimilar medication switching for the treatment of Inflammatory Bowel Disease in a resource-conscious setting.ECCO’23 CopenhagenYear: 2023
Authors: Ryan, K.(1);Hou, J.K.(2,3)*;Baker, J.(4);Krenz, C.(1);De Vries, R.(1);Waljee, A.K.(4,5);
(1)University of Michigan, Center for Bioethics and Social Sciences in Medicine, Ann Arbor, United States;(2)Michael E. DeBakey VA Medical Center, Center for Innovations in Quality- Effectiveness- and Safety, Houston, United States;(3)Baylor College of Medicine, Department of Gastroenterology, Houston, United States;(4)Ann Arbor VA Healthcare System, Center for Clinical Management Research, Ann Arbor, United States;(5)University of Michigan, Department of Gastroenterology, Ann Arbor, United States;
P601: Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary projectECCO’23 CopenhagenYear: 2023
Authors: Martins, A.(1);Silva, F.(2);Canelas, G.(2);Ribeiro, L.(3);Pinto, S.(3);Sarmento, A.(3);Magro, F.(4);Ferreira de Abreu, C.M.(5)*;
(1)São João Hospital Center- Porto- Portugal Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal Instituto de Inovação e Investigação em Saúde I3S- Portugal d Instituto Nacional de Engenharia Biomédica INEB- Portugal, Infectious Diseases, Porto, Portugal;(2)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(3)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(4)Department of Biomedicine- Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal. Department of Gastroenterology- São João Hospital Center- Porto- Portugal. Clinical Pharmacology Unit- São João Hospital Center- Porto- Portugal, Department of Gastroenterology, Porto, Portugal;(5)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal., Department of Infectious Diseases, Porto, Portugal;
P602: Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Magro, F.(1)*;Peyrin-Biroulet, L.(2,3);Sands, B.E.(4);Danese, S.(5);Jairath, V.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Ferreira Branquinho, D.(10);Modesto, I.(11);Feagan, B.G.(12);
(1)São João Hospital Center & University of Porto, Gastroenterology, Porto, Portugal;(2)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(3)Groupe Hospitalier privé Ambroise Paré - Hartmann- Paris IBD center, Gastroenterology, Neuilly sur Seine, France;(4)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Western University, Gastroenterology, London- Ontario, Canada;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Healthcare India Pvt. Ltd., Biostatistics, Chennai, India;(9)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Lisbon, Portugal;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(12)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;
P603: Real-world Scottish experience of anti-TNF therapy in paediatric Crohn's disease 2016-2020 against the ECCO-ESPGHAN recommendationsECCO’23 CopenhagenYear: 2023
Authors: Wands , D.(1)*;Scott , G.(2);Wilson , D.C.(1);Hansen , R.(2);Chalmers , I.(3);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(2)Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;(3)Royal Aberdeen Children's Hospital, Department of Paediatric Gastroenterology, Aberdeen, United Kingdom;
P605: Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative studyECCO’23 CopenhagenYear: 2023
Authors: Resál, T.(1);Bacsur, P.(2);Bor, R.(2);Bálint, A.(2);Katsanos, K.(3);Michalopoylos, G.(4);Ribaldone, D.G.(5);Attauabi, M.(6);Mirabella , Z.(7);Yanai, H.(8);Bezzio, C.(9);Castiglione, F.(10);Bar-Gil Shitrit, A.(11);Pugliese, D.(12);Lakatos, P.L.(13,14);Savarino, E.(15);Lukáš, M.(16);Franko, M.(17);Chashkova, E.(18);Molander, P.(19);Nancey, S.(20);Bannon, L.(21);Krznaric, Z.(22);Filip, R.(23);Szamosi, T.(24);Kaštylová, K.(25);Sarlós, P.(26);Ami-Barak, H.(8);Rispo, A.(27);Limdi, J.(28);Kagramanova, A.(29);Szepes, Z.(2);Farkas, K.(2);Molnár, T.(30)*;
(1)University of Szeged, Ist Department of internal medicine, Szeged, Hungary;(2)Szent-Györgyi Albert Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(3)University of Ioannina School of Health Sciences, Department of Internal Medicine- Faculty of Medicine, Ioannina, Greece;(4)General Hospital of Athens "G. Gennimatas", Gastroenterology Department, Athens, Greece;(5)University of Turin, Department of Medical Science, Turin, Italy;(6)Copenhagen University Hospital - Herlev and Gentofte, Department of gastroenterology, Herlev, Denmark;(7)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit, Hvidovre, Denmark;(8)Rabin Medical Center, Division of Gastroenterology, Tel Aviv, Israel;(9)Rho Hospital- Asst Rhodense, IBD Unit/Gastroenterology Unit, Rho, Italy;(10)Clinical Medicine and Surgery AOU Federico II of Naples, IBD Unit Department, Naples, Italy;(11)Shaare Zedek Medical Center- Hebrew University of Jerusalem, Digestive diseases institute, Jerusalem, Israel;(12)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Rome, Unità Operativa Complessa di Medicina Interna e Gastroenterologia- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(13)McGill University Health Centre- Montreal General Hospital, Division of Gastroenterology, Montreal, Canada;(14)Semmelweiss University, Department of Internal Medicine and Oncology, Budapest, Hungary;(15)Department of Surgery- Oncology and Gastroenterology, University of Padova, Padova, Hungary;(16)Charles University in Prague, IVth Medical Department, Prague, Czech Republic;(17)University of Ljubljana, Medical Faculty, Ljubljana, Slovenia;(18)Scientific Center of Surgery and Traumatology, Irkutsk, Irkutsk, Russian Federation;(19)Helsinki University Hospital, Abdominal center- Gastroenterology, Helsinki, Finland;(20)Hôpital Lyon Sud, Service d'hépato gastroentérologie, Lyon, France;(21)Tel Aviv medical center, Department of Gastroenterology and Hepatology, Tel Aviv, Israel;(22)Clinical Hospital Centre & School of Medicine Zagreb, Department of Gastroenterology- Hepatology and Nutrition, Zagreb, Croatia;(23)Unit of Clinical Hospital No. 2, Department of Gastroenterology with IBD, Rzeszow, Poland;(24)Military Hospital - State Health Centre- Budapest, Department of Gastroenterology, Budapest, Hungary;(25)ISCARE a.s.- Prague, IBD Clinical and Research Centre, Prague, Czech Republic;(26)University of Pécs, First Department of Medicine, Pécs, Hungary;(27)University "Federico II" of Naples, Gastroenterology IBD Unit, Naples, Italy;(28)Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom;(29)Clinical Research Center of Moscow, IBD department, Moscow, Russian Federation;(30)Szent-Györgyi Albert Medical School, Department of Medicine, Szeged, Hungary;
P606: Significant regional differences in referral patterns for bowel resection in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Iesalnieks, I.(1)*;Adamou, A.(2);Magdalena, B.(2);Streetz, K.(3);
(1)Evangelisches Krankenhaus Kalk, Department of surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk, Surgery, Cologne, Germany;(3)Evangelisches Krankenhaus kalk, Gastroenterology, Cologne, Germany;
P607: HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Doherty, J.(1)*;Ryan, A.(2);Quinn, E.(2);Dolan, J.(2);Corcoran, R.(3);O' Hara, F.(4);Bailey, Y.(4);McNamara, D.(4);Doherty, G.(5);Kevans, D.(3);
(1)St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland;(2)Genuity Science Ireland Limited, Inflammatory Bowel Disease, Dublin, Ireland;(3)St James Hospital, Department of Gastroenterology, Dublin, Ireland;(4)Tallaght University Hospital- Dublin- Ireland, Department of Gastroenterology, Dublin, Ireland;(5)Centre for Colorectal Disease- St Vincent's University Hospital & School of Medicine- University College Dublin, Department of Gastroenterology and School of Medicine- University College Dublin, Dublin, Ireland;Trinity Academic Gastroenterology Group School of Medicine Trinity College Dublin Ireland. Wellcome-HRB Clinical Research Facility St James's Hospital Dublin Ireland. INITIative IBD research network (www.initiativeibd.ie)
P608: Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
(1)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents- and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(4)Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Stanford, United States;
P609: Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Rubin, D.T.(2);Vermeire, S.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Dignass, A.(5);Regueiro, R.(6);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(3)University of Leuven, Chronic Diseases and Metabolism, Leuven, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(6)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)ECCO’23 CopenhagenYear: 2023
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
(1)Guy's and St Thomas' Hospital- Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Pfizer Inc., Inflammation and Immunology, New York, United States;(3)EVERSANA Pvt. Ltd, HEOR/Real-world Evidence, Mumbai, India;(4)Pfizer Inc., Gastroenterology- Inflammation and Immunology, Collegeville- PA, United States;(5)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)ECCO’23 CopenhagenYear: 2023
Authors: Muñoz Nuñez, J.F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Casellas, F.(6);
(1)Complejo Asistencial Universitario de Salamanca, Digestive Service, Salamanca, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IIS-Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain;(4)Hospital de Santa Maria- Centro Hospitalar Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisbon, Spain;(5)Takeda Farmacéutica España, Medical Department, Madrid, Spain;(6)Hospital Universitari Vall d'Hebron, Crohn-Colitis Care Unit UACC, Barcelona, Spain;
P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD StudyECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;Principi, M.(2);Facciotti, F.(3);Contaldo, A.(4);Todeschini, A.(5);Bezzio, C.(6);Saibeni, S.(6);Castiglione, F.(7);Nardone, O.M.(7);Spagnuolo, R.(8);Fantini, M.C.(9);Riguccio, G.(10);Conforti, F.S.(11);Caprioli, F.A.(11);Viganò, C.(12);Felice, C.(13);Fiorino, G.(14);Correale, C.(15);Bodini, G.(16);Milla, M.(17);Scardino, G.(18);Vernero, M.(19);Desideri, F.(20);Bossa, F.(21);Guerra, M.(21);Ventimiglia, M.(22);Mannino, M.(1);Rizzo, G.(23);Orlando, A.(1);
(1)"Villa Sofia-Cervello" Hospital, IBD Unit, Palermo, Italy;(2)“Aldo Moro” University, Gastroenterology Department, Bari, Italy;(3)Istituto Europeo di Oncologia IRCCS, Dipartimento di Oncologia Sperimentale, Milan, Italy;(4)IRCCS “S. De Bellis”, Gastroenterology 2 Unit-, Castellana Grotte- Bari, Italy;(5)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar- Verona, Italy;(6)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Rho- Milan, Italy;(7)Università Federico II di Napoli, Dipartimento di Medicina Clinica e Chirurgia, Napoli, Italy;(8)Università “Magna Graecia”, Dipartimento di Medicina Sperimentale e Clinica-, Catanzaro, Italy;(9)Università di Cagliari, Dipartimento di Scienze Mediche e Sanità Pubblica-, Cagliari, Italy;(10)Ospedale Santa Maria del Prato, UOSD Malattie Infiammatorie Croniche intestinali, Feltre, Italy;(11)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(12)University of Milano-Bicocca, Division of Gastroenterology and Center for Autoimmune Liver Diseases- Department of Medicine and Surgery, Monza, Italy;(13)Ospedale Ca'Foncello, UO Gastroenterologia, Treviso, Italy;(14)IRCCS Ospedale San Raffaele e Università Vita-Salute San Raffaele, Dipartimento di Gastroenterologia ed Endoscopia Digestiva, Milan, Italy;(15)Humanitas Clinical and Research Center, Irccs, Rozzano, Italy;(16)Università di Genova, IRCCS Policlinico San Martino, Genova, Italy;(17)Azienda Ospedaliero-Universitaria Careggi, IBD Referral Center- Gastroenterology Unit, Florence, Italy;(18)Ospedale Valduce, Gastroenterology Depatment, Como, Italy;(19)Department of Medical Sciences- University of Pavia, Gastroenterology Unit, Pavia, Italy;(20)San Maurizio Hospital, Gastroenterology Department-, Bolzano, Italy;(21)“Casa Sollievo della Sofferenza” Hospital- IRCCS, Division of Gastroenterology, San Giovanni Rotondo, Italy;(22)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service-, Rome, Italy;(23)University of Palermo, Gastroenterology Unit- PROMISE, Palermo, Italy;Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
P613: Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohortECCO’23 CopenhagenYear: 2023
Authors: Mcgrory, L.(1)*;Goess, C.(1);Lynch, K.(1,2);
(1)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;(2)University of Adelaide, Department of Medicine, Adelaide, Australia;
P614: Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohortECCO’23 CopenhagenYear: 2023
Authors: An, Y.K.(1)*;Fernandes, R.(1);Lindsay, N.(2);Khoo, E.(1);Pham, H.(2);Wong, K.F.(2);Thin, L.(3);Goodsall, T.(4);Bryant, R.V.(4);Wright, E.(5);Smith, R.(6);Friedman, A.(6);Begun, J.(1);
(1)Mater Hospital Brisbane, Department of Gastroenterology, Brisbane, Australia;(2)Mater Research Institute, IBD Research Group, Brisbane, Australia;(3)Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia;(4)The Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia;(5)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(6)Alfred Health, Department of Gastroenterology, Melbourne, Australia;Gastroenterology Network of Intestinal Ultrasound (GENIUS)
P616: Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohortECCO’23 CopenhagenYear: 2023
Authors: Focht, G.(1)*;Turner, S.(2);Carmon, N.(1);Lev-Tzion, R.(1);Orlanski-Meyer, E.(1);Ledder, O.(1);Yogev, D.(1);Assa, A.(3);Turner, D.(1);
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Ben Gurion University of the Negev, Ben Gurion University of the Negev, Beer Sheva, Israel;(3)Shaare Zedek Medcial Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;
P619: Inflammatory bowel disease meets fertility: a physicians and patients surveyECCO’23 CopenhagenYear: 2023
Authors: Vieujean, S.(1)*;De Vos, M.(2);D'Amico, F.(3,4);Paridaens, K.(5);Daftary, G.(6);Peyrin-Biroulet, L.(7,8);Danese, S.(3);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium;(3)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(4)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(5)Ferring International Center S.A., Ferring International Center S.A., Saint-Prex, Switzerland;(6)Ferring Pharmaceuticals A/S, International PharmaScience Center, Kastrup, Denmark;(7)University of Lorraine- CHRU-Nancy, Department of Gastroenterology, Nancy, France;(8)University of Lorraine, Inserm- NGERE, Nancy, France;
P620: Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?ECCO’23 CopenhagenYear: 2023
Authors: Mccrossan, M.(1)*;O'Moráin, N.(1,2);Kumar, L.(1,2);Rowan, C.(1);Sheridan, J.(1);Cullen, G.(1,2);Doherty, G.(1,2);Mulcahy, H.(1,2);
(1)St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland;(2)University College Dublin, School of Medicine & Medical Science, Dublin, Ireland;
